

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM693319

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
JPMorgan Chase Bank, N.A., as Collateral Agent		12/08/2021	National Banking Association: UNITED STATES
RECEIVING PARTY DATA			
Name:	Synexus Clinical Research US, Inc.		
Street Address:	2 Walnut Grove Drive		
Internal Address:	Suite 375		
City:	Horsham		
State/Country:	PENNSYLVANIA		
Postal Code:	19044		
Entity Type:	Corporation: ARIZONA		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	6128809	AES	
CORRESPONDENCE DATA			
Fax Number:	2127514864		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2129061216		
Email:	angela.amaru@lw.com		
Correspondent Name:	Latham & Watkins LLP c/o Angela M. Amaru		
Address Line 1:	1271 Avenue of the Americas		
Address Line 4:	New York, NEW YORK 10020		
ATTORNEY DOCKET NUMBER:	045494-0325		
NAME OF SUBMITTER:	Angela M. Amaru		
SIGNATURE:	/s/ Angela M. Amaru		
DATE SIGNED:	12/08/2021		
Total Attachments: 4			
source=PPD - Trademark Release - 2021 TSA (Executed Version)#page1.tif			
source=PPD - Trademark Release - 2021 TSA (Executed Version)#page2.tif			
source=PPD - Trademark Release - 2021 TSA (Executed Version)#page3.tif			

CH \$40.00 6128809

RELEASE OF SECURITY INTEREST IN TRADEMARKS

This RELEASE OF SECURITY INTEREST IN TRADEMARKS (this “Release”), dated as of December 8, 2021 (the “Effective Date”), is made by JPMORGAN CHASE BANK, N.A., as collateral agent (in such capacity, the “Agent”), in favor of EVIDERA, INC., and PHARMACO INVESTMENTS, INC., ACURIAN, INC., MEDICIGROUP, INC., OPTIMAL RESEARCH, LLC and SYNEXUS CLINICAL RESEARCH US, INC. (each a “Grantor” and collectively, the “Grantors”). All capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Trademark Security Agreement (whether defined therein or by reference to another agreement).

WHEREAS, pursuant to that certain Security Agreement by and among the Grantors, the Agent, and certain other parties, dated as of January 13, 2021 (as may have been amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), the Grantors executed and delivered a Trademark Security Agreement, dated as of January 13, 2021 (the “Trademark Security Agreement”), which was recorded in the United States Patent and Trademark Office (“USPTO”) on January 13, 2021 at Reel/Frame 7161/0169 (with respect to Synexus Clinical Research US, Inc.), at Reel/Frame 7235/0672 (with respect to Pharmaco Investments, Inc.), at Reel/Frame 7161/0179 (with respect to Optimal Research, LLC), at Reel/Frame 7161/0382 (with respect to MediciGroup, Inc.), at Reel/Frame 7161/0402 (with respect to Evidera, Inc.), and at Reel/Frame 7161/0159 (with respect to Acurian, Inc.);

WHEREAS, pursuant to the Security Agreement and the Trademark Security Agreement, each Grantor collaterally assigned, pledged and granted to the Agent, for the benefit of the Secured Parties, a security interest in and continuing lien on (the “Security Interest”) all of such Grantor’s right, title and interest in and to (i) all trademarks, service marks, and applications therefor, including those set forth on Schedule A hereto; (ii) all reissues, divisionals, continuations, continuations-in-part, extensions, renewals and reexaminations thereof; (iii) any and all claims for damages or injunctive relief for past, present and future infringement, dilution, misappropriation, violation or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and (iv) all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto; but excluding any Excluded Property (collectively, the “Trademark Collateral”);

WHEREAS, the Grantors have requested the Agent to release the Security Interest in the Trademark Collateral.


NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent, hereby (i) terminates the Trademark Security Agreement, (ii) releases, discharges, terminates and cancels the Security Interest in the Trademark Collateral, and (iii) re-assigns to each Grantor any right, title or interest it may have in the Trademark Collateral of such Grantor, in each case without recourse to the Agent and without representation or warranty of any kind.

Each Grantor, or any successor to such Grantor (including any person or entity hereafter holding any right, title or interest in or to the Trademark Collateral of such Grantor), is hereby authorized to record this Release in the USPTO.

[Signature Page Follows]

IN WITNESS WHEREOF, the Agent has caused this Release to be executed and delivered by its duly authorized officer as of the Effective Date.

JPMORGAN CHASE BANK, N.A., as Collateral Agent

By: 
Name: Jason Hur
Title: Executive Director



[PPD, Inc. - JPM Trademark Release]

TRADEMARK
REEL: 007523 FRAME: 0693

SCHEDULE A

Trademarks

I. Registered Trademarks

Owner	Mark	Registration Number	Country	Expiration Date
Pharmaco Investments, Inc.	"PPD" (Word Mark)	2,435,414	USA	Mar. 13, 2031
Pharmaco Investments, Inc.	"PPD" (Stylized)	2,332,313	USA	Mar. 21, 2030
Pharmaco Investments, Inc.	"PPD QUERYDIRECT"	2,644,316	USA	Oct. 29, 2022
Pharmaco Investments, Inc.	"PRECLARUS"	4,573,756	USA	Jul. 22, 2024
Pharmaco Investments, Inc.	"TRIMENTUM"	4,787,158	USA	Aug. 4, 2025
Acurian, Inc.	"ACURIAN RECRUITMENT MANAGER"	3,971,039	USA	May 31, 2021
Acurian, Inc.	"ACURIAN" (Plus Design)	2,697,439	USA	Mar. 18, 2023
Acurian, Inc.	"ACURIAN"	2,566,246	USA	Apr. 30, 2022
Acurian, Inc.	"ACURIAN HEALTH"	4,411,824	USA	Oct. 1, 2023
Acurian, Inc.		4,429,550	USA	Nov. 5, 2023
Acurian, Inc.	"ACURIAN RETENTION MANAGER"	4,621,574	USA	Oct. 14, 2024
SYNEXUS CLINICAL RESEARCH US, INC.		6,128,809	USA	Aug. 18, 2030
Optimal Research, LLC	OPTIMAL RESEARCH INTEGRATED SITE SOLUTIONS	5,129,408	USA	Jan. 24, 2027
Evidera, Inc.	"E-RS"	4,959,657	USA	May 17, 2026
Evidera, Inc.	"EVIDERA" + Design	4,555,020	USA	Jun. 24, 2024
Evidera, Inc.	"EVIDERA"	4,555,019	USA	Jun. 24, 2024
Evidera, Inc.	"EXACT-PRO INITIATIVE" + Design	4,728,703	USA	Apr. 28, 2025
Evidera, Inc.	"EVIDICE"	5,141,280	USA	Feb. 14, 2027
Evidera, Inc.	"IVALUE SUITE"	5,154,972	USA	Mar. 7, 2027
Evidera, Inc.	"ReVIDICE"	5,150,411	USA	Feb. 28, 2027
Evidera, Inc.	"THE EVIDENCE FORUM"	5,252,789	USA	Jul. 25, 2027
Evidera, Inc.	"EVIDERA" + Design	5,487,857	USA	Jan. 5, 2028

Owner	Mark	Registration Number	Country	Expiration Date
MediciGroup, Inc.	WORLDS APART, PURPLE TOGETHER	4,735,643	USA	May 12, 2025
MediciGroup, Inc.	TEAM EPILEPSY	4,160,281	USA	Jun. 19, 2022
MediciGroup, Inc.	STUDYCOORDINATOR.NET	3,987,441	USA	Jun. 28, 2021
MediciGroup, Inc.	L2FU	4,018,286	USA	Aug. 30, 2021
MediciGroup, Inc.	CENTER FOR PATIENT RECRUITMENT	2,956,002	USA	May 24, 2025
MediciGroup, Inc.	HEAD START TO RECRUITMENT	3,867,150	USA	Oct. 26, 2020
MediciGroup, Inc.	MEDICIGLOBAL + Design	3,864,845	USA	Oct. 19, 2020
MediciGroup, Inc.	STUDY SEMINARS	2,515,932	USA	Dec. 4, 2021
MediciGroup, Inc.	VIP	2,445,248	USA	Apr. 17, 2021
MediciGroup, Inc.	CTIP	2,360,017	USA	Jun. 20, 2020
MediciGroup, Inc.	MEDICIGROUP	2,131,963	USA	Jan. 27, 2028
MediciGroup, Inc.	SMART	2,902,264	USA	Nov. 9, 2024
Evidera, Inc. (f/k/a Fieldaccess, LLC)	LIVETRACKER	4,950,468	USA	May 3, 2022
Evidera, Inc. (f/k/a Fieldaccess, LLC)	MEDIMIX	3,138,599	USA	Oct. 17, 2026

II. Trademark Applications

None.